Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate
Authors:
- 20 August 2002
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 32 (8) , 575-580
Abstract
Background Ursodeoxycholic acid (UDCA) and its taurine conjugate (TUDCA) exert a protective effect in cholestatic liver diseases. A greater hepatoprotective effect of TUDCA has been suggested. Absorption appears to be a limiting factor and up to now has not been studied in man.Methods We studied absorption and biliary bile acid secretion and composition after administration of UDCA and TUDCA in patients who had complete extrahepatic biliary obstruction caused by pancreatic carcinoma but had no intestinal or liver disease. After 5 days of intact enterohepatic circulation eight patients with a percutaneous biliary–duodenal drainage received, during two study periods, 1000 mg (1916·9 µmol; mean 29·6 µmol kg−1) TUDCA and 750 mg (1910·4 µmol; mean 29·5 µmol kg−1) UDCA in random order. Each patient served as his own control.Results After UDCA and TUDCA administration the biliary UDCA content increased to 55·2% and 54·6% of total bile acids, respectively (not significant). Biliary secretion of cholic and chenodeoxycholic acids remained unchanged whereas that of lithocholic acid increased slightly. A total of 64·6% of the orally administered TUDCA and 55·1% of the UDCA was absorbed (not significant). After TUDCA administration, biliary UDCA was preferentially (95·4%) taurine‐conjugated whereas after UDCA administration biliary UDCA was mainly (79·8%) glycine‐conjugated.Conclusions After oral administration of TUDCA and UDCA, no significant differences in their absorption and in biliary bile acid secretion exist. Whether biliary enrichment with taurine conjugates of UDCA instead of glycine conjugates offers advantages in the treatment of cholestatic liver disease is unclear at present.Keywords
This publication has 48 references indexed in Scilit:
- A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitisGastroenterology, 2001
- High-Dose Ursodeoxycholic Acid as a Therapy for Patients With Primary Sclerosing CholangitisAmerican Journal of Gastroenterology, 2001
- Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosisGastroenterology, 1997
- Ursodiol for Primary Sclerosing CholangitisNew England Journal of Medicine, 1997
- Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitisJournal of Hepatology, 1997
- Ursodeoxycholic acid in the treatment of primary biliary cirrhosisGastroenterology, 1994
- Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study periodJournal of Hepatology, 1994
- Ursodeoxycholic Acid for Treatment of Primary Sclerosing Cholangitis: A Placebo–Controlled TrialHepatology, 1992
- A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary CirrhosisNew England Journal of Medicine, 1991
- Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trialGastroenterology, 1989